Vascular Endothelial Growth Factor (VEGF) Impairs the Motility and Immune Function of Human Mature Dendritic Cells Through the VEGF Receptor 2-RhoA-cofilin1 Pathway

Overview

Journal Cancer Sci

Specialty Oncology

Date 2019 Jun 7

PMID 31169331

Citations 36

Authors

Jinhua Long

Zuquan Hu

Hui Xue

Yun Wang

Jin Chen

Fuzhou Tang

Jing Zhou

Lina Liu

Wei Qiu

Shichao Zhang

Yan Ouyang

Yuannong Ye

Guoqiang Xu

Long Li

Zhu Zeng

Affiliations

Soon will be listed here.

Abstract

Dendritic cells (DCs) are potent and specialized antigen presenting cells, which play a crucial role in initiating and amplifying both the innate and adaptive immune responses against cancer. Tumor cells can escape from immune attack by secreting suppressive cytokines that solely or cooperatively impair the immune function of DCs. However, the underlying mechanisms are not fully defined. Vascular endothelial growth factor (VEGF) has been identified as a major cytokine in the tumor microenvironment. To elucidate the effects of VEGF on the motility and immune function of mature DCs (mDCs), the cells were treated with 50 ng/mL VEGF and investigated by proteomics and molecular biological technologies. The results showed that VEGF can impair the migration capacity and immune function of mDCs through the RhoA-cofilin1 pathway mediated by the VEGF receptor 2, suggesting impaired motility of mDCs by VEGF is one of the aspects of immune escape mechanisms of tumors. It is clinically important to understand the biological behavior of DCs and the immune escape mechanisms of tumor as well as how to improve the efficiency of antitumor therapy based on DCs.

Citing Articles

Immune Cell Engagers: Advancing Precision Immunotherapy for Cancer Treatment.

In H, Park M, Lee H, Han K Antibodies (Basel). 2025; 14(1).

PMID: 39982231 PMC: 11843982. DOI: 10.3390/antib14010016.

Cross-priming in cancer immunology and immunotherapy.

Luri-Rey C, Teijeira A, Wculek S, de Andrea C, Herrero C, Lopez-Janeiro A Nat Rev Cancer. 2025; .

PMID: 39881005 DOI: 10.1038/s41568-024-00785-5.

Adenosine A2AR in viral immune evasion and therapy: unveiling new avenues for treating COVID-19 and AIDS.

Atif M, Alsrhani A, Naz F, Ullah S, Abdalla A, Ullah M Mol Biol Rep. 2024; 51(1):894.

PMID: 39115571 DOI: 10.1007/s11033-024-09839-1.

Dendritic Cells: A Bridge between Tolerance Induction and Cancer Development in Transplantation Setting.

Troise D, Infante B, Mercuri S, Catalano V, Ranieri E, Stallone G Biomedicines. 2024; 12(6).

PMID: 38927447 PMC: 11200833. DOI: 10.3390/biomedicines12061240.

DNA-PKcs Phosphorylates Cofilin2 to Induce Endothelial Dysfunction and Microcirculatory Disorder in Endotoxemic Cardiomyopathy.

Du Y, Zhu P, Li Y, Yu J, Xia T, Chang X Research (Wash D C). 2024; 7:0331.

PMID: 38550779 PMC: 10976589. DOI: 10.34133/research.0331.

References

Schiff D, Wen P . The siren song of bevacizumab: swan song or clarion call?. Neuro Oncol. 2018; 20(2):147-148. PMC: 5777485. DOI: 10.1093/neuonc/nox244. View

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

Ellis L, Hicklin D . VEGF-targeted therapy: mechanisms of anti-tumour activity. Nat Rev Cancer. 2008; 8(8):579-91. DOI: 10.1038/nrc2403. View

Palucka K, Banchereau J . Cancer immunotherapy via dendritic cells. Nat Rev Cancer. 2012; 12(4):265-77. PMC: 3433802. DOI: 10.1038/nrc3258. View

Long J, Hu Z, Xue H, Wang Y, Chen J, Tang F . Vascular endothelial growth factor (VEGF) impairs the motility and immune function of human mature dendritic cells through the VEGF receptor 2-RhoA-cofilin1 pathway. Cancer Sci. 2019; 110(8):2357-2367. PMC: 6676124. DOI: 10.1111/cas.14091. View

Ohm J, Gabrilovich D, Sempowski G, Kisseleva E, Parman K, Nadaf S . VEGF inhibits T-cell development and may contribute to tumor-induced immune suppression. Blood. 2003; 101(12):4878-86. DOI: 10.1182/blood-2002-07-1956. View

Eisenbarth S . Dendritic cell subsets in T cell programming: location dictates function. Nat Rev Immunol. 2018; 19(2):89-103. PMC: 7755085. DOI: 10.1038/s41577-018-0088-1. View

Kowanetz M, Ferrara N . Vascular endothelial growth factor signaling pathways: therapeutic perspective. Clin Cancer Res. 2006; 12(17):5018-22. DOI: 10.1158/1078-0432.CCR-06-1520. View

Assoun S, Brosseau S, Steinmetz C, Gounant V, Zalcman G . Bevacizumab in advanced lung cancer: state of the art. Future Oncol. 2017; 13(28):2515-2535. DOI: 10.2217/fon-2017-0302. View

10.

Fan Y, Arif A, Gong Y, Jia J, Eswarappa S, Willard B . Stimulus-dependent phosphorylation of profilin-1 in angiogenesis. Nat Cell Biol. 2012; 14(10):1046-56. PMC: 3619429. DOI: 10.1038/ncb2580. View

11.

Dikov M, Ohm J, Ray N, Tchekneva E, Burlison J, Moghanaki D . Differential roles of vascular endothelial growth factor receptors 1 and 2 in dendritic cell differentiation. J Immunol. 2004; 174(1):215-22. DOI: 10.4049/jimmunol.174.1.215. View

12.

Verdijk P, Van Veelen P, de Ru A, Hensbergen P, Mizuno K, Koerten H . Morphological changes during dendritic cell maturation correlate with cofilin activation and translocation to the cell membrane. Eur J Immunol. 2004; 34(1):156-64. DOI: 10.1002/eji.200324241. View

13.

Gabrilovich D, Ishida T, Oyama T, Ran S, Kravtsov V, Nadaf S . Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood. 1998; 92(11):4150-66. View

14.

Nagai S, Moreno O, Smith C, Ivanchuk S, Romagnuolo R, Golbourn B . Role of the cofilin activity cycle in astrocytoma migration and invasion. Genes Cancer. 2012; 2(9):859-69. PMC: 3352151. DOI: 10.1177/1947601911431839. View

15.

Villablanca E, Raccosta L, Zhou D, Fontana R, Maggioni D, Negro A . Tumor-mediated liver X receptor-alpha activation inhibits CC chemokine receptor-7 expression on dendritic cells and dampens antitumor responses. Nat Med. 2009; 16(1):98-105. DOI: 10.1038/nm.2074. View

16.

Worbs T, Hammerschmidt S, Forster R . Dendritic cell migration in health and disease. Nat Rev Immunol. 2016; 17(1):30-48. DOI: 10.1038/nri.2016.116. View

17.

Steinman R, Banchereau J . Taking dendritic cells into medicine. Nature. 2007; 449(7161):419-26. DOI: 10.1038/nature06175. View

18.

Steinman R . Decisions about dendritic cells: past, present, and future. Annu Rev Immunol. 2011; 30:1-22. DOI: 10.1146/annurev-immunol-100311-102839. View

19.

Kobayashi M, Azuma E, Ido M, Hirayama M, Jiang Q, Iwamoto S . A pivotal role of Rho GTPase in the regulation of morphology and function of dendritic cells. J Immunol. 2001; 167(7):3585-91. DOI: 10.4049/jimmunol.167.7.3585. View

20.

Wu J, Tang Y, Liang X . Targeting VEGF pathway to normalize the vasculature: an emerging insight in cancer therapy. Onco Targets Ther. 2018; 11:6901-6909. PMC: 6200071. DOI: 10.2147/OTT.S172042. View